13 April 2026 | Health Insurance | 5 min read
The IA Is Reviewing Medical Insurance. Here Is What Our Clients Are Actually Asking Us.
Hong Kong’s Insurance Authority has confirmed it is conducting a formal review of medical insurance products, with a focus on coverage, affordability, and consumer protection. As a broker talking to employers and families in this city every day, we have a fairly clear view of why this review is happening — and what it does and does not change for clients right now.
What the IA Is Actually Doing
At the recent Asia Healthcare and Health Insurance Conference, the IA made clear that it intends to use stronger data analysis to understand how medical plans are priced and how well they genuinely protect consumers. The regulator wants to see more accessible, modular products — and it is asking insurers a pointed question: are rising premiums still delivering fair value and meaningful protection?
It is the right question. And it is one we ask on behalf of our clients at every renewal.
What We Are Hearing From Clients This Week
Three themes have come up repeatedly in our conversations over the past few weeks, and they cut across both corporate and individual clients.
Employers — especially SMEs — feel caught in the middle. Group medical renewals are coming in higher, reflecting both increased usage and rising underlying costs. Several HR and finance teams have told us they feel stuck between protecting their staff and protecting their budgets. The options on the table rarely feel straightforward.
Individuals and families are thinking longer-term. The question we are hearing more often is not just “what does my plan cover?” but “can I realistically keep this level of cover for the next five years?” That is especially true for clients on international or higher-end private hospital plans, where premium trajectories are steeper.
There is growing appetite for flexibility. Clients increasingly want products that let them adjust benefits at renewal — adding or removing specific covers — rather than facing a binary accept-or-cancel decision. The all-or-nothing model is frustrating people, and understandably so.
What the IA Review Can and Cannot Do
The IA’s review is a genuinely positive development, and we support it. Better disclosure, clearer product design, and a wider range of options for different budgets are all things this market needs.
But the review will not, by itself, stop medical inflation. The underlying cost drivers — advances in treatment technology, new drugs, an ageing population, and a public system under sustained pressure — are structural. They will not be resolved by regulation alone, and they will not resolve quickly.
That means the practical work of managing your health insurance still needs to happen at the individual level, with someone who knows your situation and can sit on your side of the table.
What Our Role Is — and What We Can Do for You Now
Our job as your broker is not just to find you a policy. It is to help you understand where your premium is actually going, which benefits are genuinely essential for your situation, and where there is room to adjust without leaving gaps that matter. That conversation looks different for a 40-person SME than it does for a family of four — and it should.
If you are due for renewal in the next six to twelve months, this is the right moment to start that conversation early. We can benchmark your current plan against what is available in the Hong Kong market right now, walk you through how the IA’s review may affect product offerings going forward, and work with you on practical adjustments — from benefit design to wellness initiatives — that keep your cover sustainable without hollowing it out.
Reach out to your usual Navigator contact, and we will walk through your options in plain language. No jargon, no pressure — just a clear picture of where you stand and what your choices are.
